172 related articles for article (PubMed ID: 32900604)
1. Characterizing patient-oncologist communication in genomic tumor testing: The 21-gene recurrence score as an exemplar.
O'Neill SC; Vadaparampil ST; Street RL; Moore TF; Isaacs C; Han HS; Augusto B; Garcia J; Lopez K; Brilleman M; Jayasekera J; Eggly S
Patient Educ Couns; 2021 Feb; 104(2):250-256. PubMed ID: 32900604
[TBL] [Abstract][Full Text] [Related]
2. Prospective Evaluation of the 21-Gene Recurrence Score Assay for Breast Cancer Decision-Making in Ontario.
Levine MN; Julian JA; Bedard PL; Eisen A; Trudeau ME; Higgins B; Bordeleau L; Pritchard KI
J Clin Oncol; 2016 Apr; 34(10):1065-71. PubMed ID: 26598746
[TBL] [Abstract][Full Text] [Related]
3. Conveying genomic recurrence risk estimates to patients with early-stage breast cancer: oncologist perspectives.
Spellman E; Sulayman N; Eggly S; Peshkin BN; Isaacs C; Schwartz MD; O'Neill SC
Psychooncology; 2013 Sep; 22(9):2110-6. PubMed ID: 23447452
[TBL] [Abstract][Full Text] [Related]
4. Oncologists' influence on receipt of adjuvant chemotherapy: does it matter whom you see for treatment of curable breast cancer?
Katz SJ; Hawley ST; Bondarenko I; Jagsi R; Ward KC; Hofer TP; Kurian AW
Breast Cancer Res Treat; 2017 Oct; 165(3):751-756. PubMed ID: 28689364
[TBL] [Abstract][Full Text] [Related]
5. Multilevel Influences on Patient-Oncologist Communication about Genomic Test Results: Oncologist Perspectives.
O'Neill SC; Taylor KL; Clapp J; Jayasekera J; Isaacs C; Mary Atieh Graham D; Goldberg SL; Mandelblatt J
J Health Commun; 2018; 23(7):679-686. PubMed ID: 30130477
[TBL] [Abstract][Full Text] [Related]
6. Effect of a Skills Training for Oncologists and a Patient Communication Aid on Shared Decision Making About Palliative Systemic Treatment: A Randomized Clinical Trial.
Henselmans I; van Laarhoven HWM; van Maarschalkerweerd P; de Haes HCJM; Dijkgraaf MGW; Sommeijer DW; Ottevanger PB; Fiebrich HB; Dohmen S; Creemers GJ; de Vos FYFL; Smets EMA
Oncologist; 2020 Mar; 25(3):e578-e588. PubMed ID: 32162796
[TBL] [Abstract][Full Text] [Related]
7. The 21-Gene Recurrence Score Assay for Node-Positive, Early-Stage Breast Cancer and Impact of RxPONDER Trial on Chemotherapy Decision-Making: Have Clinicians Already Decided?
Jasem J; Fisher CM; Amini A; Shagisultanova E; Rabinovitch R; Borges VF; Elias A; Kabos P
J Natl Compr Canc Netw; 2017 Apr; 15(4):494-503. PubMed ID: 28404760
[No Abstract] [Full Text] [Related]
8. Impact of 21-Gene Breast Cancer Assay on Treatment Decision for Patients with T1-T3, N0-N1, Estrogen Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE Study.
Dieci MV; Guarneri V; Zustovich F; Mion M; Morandi P; Bria E; Merlini L; Bullian P; Oliani C; Gori S; Giarratano T; Orvieto E; Griguolo G; Michieletto S; Saibene T; Del Bianco P; De Salvo GL; Conte P;
Oncologist; 2019 Nov; 24(11):1424-1431. PubMed ID: 31152079
[TBL] [Abstract][Full Text] [Related]
9. Impacts of Early Guideline-Directed 21-Gene Recurrence Score Testing on Adjuvant Therapy Decision Making.
Dzimitrowicz H; Mougalian S; Storms S; Hurd S; Chagpar AB; Killelea BK; Horowitz NR; Lannin DR; Harigopal M; Hofstatter E; DiGiovanna MP; Adelson KB; Silber A; Abu-Khalaf M; Chung G; Zaheer W; Abdelghany O; Hatzis C; Pusztai L; Sanft TB
J Oncol Pract; 2017 Dec; 13(12):e1012-e1020. PubMed ID: 29048991
[TBL] [Abstract][Full Text] [Related]
10. Impact of 21-gene recurrence score testing on adjuvant chemotherapy decision making in older patients with breast cancer.
Zeng Y; Gao W; Lin L; Chen X; Shen K
J Geriatr Oncol; 2020 Jun; 11(5):843-849. PubMed ID: 31704037
[TBL] [Abstract][Full Text] [Related]
11. First Prospective Multicenter Italian Study on the Impact of the 21-Gene Recurrence Score in Adjuvant Clinical Decisions for Patients with ER Positive/HER2 Negative Breast Cancer.
Dieci MV; Guarneri V; Giarratano T; Mion M; Tortora G; De Rossi C; Gori S; Oliani C; Merlini L; Pasini F; Bonciarelli G; Griguolo G; Orvieto E; Michieletto S; Saibene T; Del Bianco P; De Salvo GL; Conte P
Oncologist; 2018 Mar; 23(3):297-305. PubMed ID: 29133514
[TBL] [Abstract][Full Text] [Related]
12. Is There a Relationship between Shared Decision Making and Breast Cancer Patients' Trust in Their Medical Oncologists?
Engelhardt EG; Smets EMA; Sorial I; Stiggelbout AM; Pieterse AH; Hillen MA
Med Decis Making; 2020 Jan; 40(1):52-61. PubMed ID: 31789100
[No Abstract] [Full Text] [Related]
13. Should women with early breast cancer under 40 years of age have a routine 21-gene recurrence score testing: A SEER database study.
Liu KH; Zhang L; Chen JX; Lian CL; Wang J; He ZY; Wu SG
Breast; 2020 Feb; 49():233-241. PubMed ID: 31918322
[TBL] [Abstract][Full Text] [Related]
14. Breast medical oncologists' use of standard prognostic factors to predict a 21-gene recurrence score.
Kamal AH; Loprinzi CL; Reynolds C; Dueck AC; Geiger XJ; Ingle JN; Carlson RW; Hobday TJ; Winer EP; Goetz MP
Oncologist; 2011; 16(10):1359-66. PubMed ID: 21934103
[TBL] [Abstract][Full Text] [Related]
15. The impact of the 21-gene recurrence score (Oncotype DX) on concordance of adjuvant therapy decision making as measured by the Liverpool Systemic Therapy Adjuvant Decision Tool.
Olsson-Brown A; Piskilidis P; O'Hagan J; Thorp N; Robson P; Innes H; Wong H; Cicconi S; Jackson R; Kiernan T; Holcombe C; O'Reilly S; Palmieri C
Breast; 2019 Apr; 44():94-100. PubMed ID: 30703670
[TBL] [Abstract][Full Text] [Related]
16. Second Opinions From Medical Oncologists for Early-Stage Breast Cancer: Prevalence, Correlates, and Consequences.
Kurian AW; Friese CR; Bondarenko I; Jagsi R; Li Y; Hamilton AS; Ward KC; Katz SJ
JAMA Oncol; 2017 Mar; 3(3):391-397. PubMed ID: 28033448
[TBL] [Abstract][Full Text] [Related]
17. Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection.
Lo SS; Mumby PB; Norton J; Rychlik K; Smerage J; Kash J; Chew HK; Gaynor ER; Hayes DF; Epstein A; Albain KS
J Clin Oncol; 2010 Apr; 28(10):1671-6. PubMed ID: 20065191
[TBL] [Abstract][Full Text] [Related]
18. Patient-Centered Communication for Discussing Oncotype DX Testing.
Roberts MC; Bryson A; Weinberger M; Dusetzina SB; Dinan MA; Reeder-Hayes KE; Wheeler SB
Cancer Invest; 2016 May; 34(5):205-12. PubMed ID: 27124287
[TBL] [Abstract][Full Text] [Related]
19. The impact of Oncotype DX breast cancer assay results on clinical practice: a UK experience.
Crolley VE; Marashi H; Rawther S; Sirohi B; Parton M; Graham J; Vinayan A; Sutherland S; Rigg A; Wadhawan A; Harper-Wynne C; Spurrell E; Bond H; Raja F; King J
Breast Cancer Res Treat; 2020 Apr; 180(3):809-817. PubMed ID: 32170635
[TBL] [Abstract][Full Text] [Related]
20. A randomized controlled trial of a skills training for oncologists and a communication aid for patients to stimulate shared decision making about palliative systemic treatment (CHOICE): study protocol.
Henselmans I; Smets EMA; de Haes JCJM; Dijkgraaf MGW; de Vos FY; van Laarhoven HWM
BMC Cancer; 2018 Jan; 18(1):55. PubMed ID: 29310605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
